India, March 23 -- India's semaglutide market has seen heightened competition, with the expiration of the patent causing a flood of generics at discounted prices. The prices vary between Rs 1,290 and Rs 8,000 monthly. Analysts at Goldman Sachs, Macquarie, and CLSA rate Sun Pharma and Torrent Pharma highly to benefit from the large market size and volumes. Price disruption has opened up the market The semaglutide market in India has started a new chapter after the patent expiry of the drug. Several local pharmaceutical companies have started launching generic versions of the drug at significantly discounted prices. The most notable change in the market is the price factor. The prices of the generic versions of the drug range from Rs 1,29...